About: Exposure to DPP‐4 inhibitors and COVID‐19 among people with type 2 diabetes. A case

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Exposure to DPP‐4 inhibitors and COVID‐19 among people with type 2 diabetes. A case–control study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Exposure to DPP‐4 inhibitors and COVID‐19 among people with type 2 diabetes. A case–control study
Creator	Affiliations, Vianello, Andrea Avogaro, Angelo Cattelan, Anna Fioretto, Paola Vettor, Roberto Bonora, Benedetta Costantini, Giorgia Fadini, Gian Falaguasta, Daniele Morieri, Mario Pinelli, Silvia Selmin, Elisa Tresso, Silvia Voltan, Giacomo Camillo, Barbara Longato, Enrico Sparacino, Giovanni Tramontan, Lara
source	Medline; PMC; WHO
abstract	Because other coronaviruses enter the cells by binding to dipeptidyl‐peptidase‐4 (DPP‐4), it has been speculated that DPP‐4 inhibitors (DPP‐4i) may exert an activity against SARS‐CoV‐2. In the absence of clinical trial results, we analyzed epidemiological data to support or discard such hypothesis. We retrieved information on exposure to DPP‐4i among patients with type 2 diabetes (T2D) hospitalized for COVID‐19 at an outbreak hospital in Italy. As reference, we retrieved exposure to DPP‐4i among matched T2D patients in the same Region. Of 403 hospitalized COVID‐19 patients, 85 had T2D. The rate of exposure to DPP‐4i was similar between T2D patients with COVID‐19 (10.6%) and 14 857 matched patients in the Region (8.8%), or 793 matched patients in the local outpatient clinic (15.4%), 8284 matched patients hospitalized for other reasons (8.5%), and when comparing 71 patients hospitalized for COVID‐19 pneumonia (11.3%) to 351 matched patients with pneumonia of other etiology (10.3%). T2D patients with COVID‐19 who were on DPP‐4i had a similar disease outcome as those who were not. In summary, we found no evidence that DPP‐4i might affect hospitalization for COVID‐19. This article is protected by copyright. All rights reserved.
has issue date	2020-05-28(xsd:dateTime)
bibo:doi	10.1111/dom.14097
bibo:pmid	32463179
has license	no-cc
sha1sum (hex)	c00623b3cff6a2c744b31aeccace9229a3e74676
schema:url	https://doi.org/10.1111/dom.14097
resource representing a document's title	Exposure to DPP‐4 inhibitors and COVID‐19 among people with type 2 diabetes. A case–control study
has PubMed Central identifier	PMC7283835
has PubMed identifier	32463179
schema:publication	Diabetes Obes Metab
resource representing a document's body	covid:c00623b3cff6a2c744b31aeccace9229a3e74676#body_text
is schema:about of	named entity 'COVID-19' named entity 'type 2 diabetes' named entity 'case-control study' named entity 'COVID-19' named entity 'type 2 diabetes' named entity 'clinically meaningful' named entity 'beta blockers' named entity 'spike protein' named entity 'T2D' named entity 'SARS-CoV-2 outbreak' named entity 'DPP-4' named entity 'SARS-CoV' named entity 'DPP-4' named entity 'Padova' named entity 'COVID-19' named entity 'ascertainment bias' named entity 'COVID' named entity 'glucocorticoids' named entity 'chronic obstructive pulmonary disease' named entity 'CD26' named entity 'diabetic' named entity 'calcium channel blockers' named entity 'DPP-4' named entity 'hydroxychloroquine' named entity 'lymphocytes' named entity 'COVID' named entity 'chronic kidney disease' named entity 'diabetes' named entity 'diabetes' named entity 'chi-square test' named entity 'treatment options' named entity 'insulin' named entity 'hypoxia' named entity 'T2D' named entity 'Veneto Region' named entity 'cardiovascular disease' named entity 'retrospective study' named entity 'disease outcome' named entity 'sample size' named entity 'COVID' named entity 'SAS' named entity 'T2D' named entity 'immune responses' named entity 'platelet aggregation inhibitors' named entity 'diabetes' named entity 'control patients' named entity '5.7' named entity 'infection' named entity 'comorbidities' named entity 'DPP-4' named entity 'odds ratios' named entity 'microangiopathy' named entity 'T2D' named entity 'SARS-CoV-2' named entity 'incretin' named entity 'coronavirus infection' named entity 'COVID' named entity 'electronic medical records' named entity 'propensity scores' named entity 'T2D' named entity 'COVID' named entity 'dyslipidemia' named entity 'beta blockers'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software